Lundbeck has potential name for migraine drug: Vyepti

Lundbeck's billion-dollar migraine drug based on eptinezumab will possibly be marketed under the name Vyepti, providing the US health authorities approve the drug later this month.

Photo: Jens Dresling/Politiken/Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles